Key Highlights: Implications: Akums’ CDSCO/DCGI approval to manufacture colchicine 0.5 mg for cardiovascular risk reduction is a “first‑time‑in‑India” regulatory milestone that lets India’...
Key Highlights: Implications: India’s GATINN catapults Servier into SPC dominance, crushing fragmented chronic therapy rivals while exploding patient compliance across emerging marke...
Key Highlights: Implications: PrecisionCHD taps India’s $1.5B+ cardiac diagnostics market (15% CAGR), challenging ECG/stress tests via molecular insights and Dr Lal’s netw...
Key Highlights: Implications: TRIA disrupts India’s heart valve market by eliminating lifelong blood thinners, handing cardiothoracic surgeons a patient-friendly alte...
